Twist Bioscience Intrinsic Stock Value – Twist Bioscience to Unveil Quarterly Earnings; Analysts Take Cautious Stance
August 3, 2023
🌧️Trending News
Twist Bioscience ($NASDAQ:TWST), a San Francisco-based synthetic biology company, is set to report its quarterly earnings, though analysts are being cautious in their expectations. Despite its challenges, the company’s outlook remains positive as it continues to invest in its technology and products to help customers accelerate their discoveries and innovations. Analysts are keeping a close eye on Twist Bioscience as they prepare for the upcoming quarterly earnings report.
While the company is optimistic about the future, the cautious stance from analysts has left many wondering how the report will impact the stock price. As investors and analysts await the results of this report, Twist Bioscience remains one to watch in the coming weeks.
Earnings
TWIST BIOSCIENCE is set to unveil its quarterly earnings report for FY2023 Q2 ending March 31 2021. The report reveals a total revenue of 31.2M USD and a net income loss of 37.92M USD. Compared to the same period of last year, there was a 35.2% decrease in total revenue.
Over the last 3 years, TWIST BIOSCIENCE has seen a rise in total revenue from 31.2M USD to 60.18M USD. Despite the steady increase in revenue, analysts are taking a cautious stance on the earning report, as the net income loss indicates a potential financial setback.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Twist Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 227.84 | -212.61 | -97.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Twist Bioscience. More…
| Operations | Investing | Financing |
| -131.8 | -232.93 | 270.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 853.92 | 149.99 | 13.18 |
Key Ratios Snapshot
Some of the financial key ratios for Twist Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 51.3% | – | -92.9% |
| FCF Margin | ROE | ROA |
| -102.1% | -17.7% | -15.5% |
Stock Price
On Monday, TWIST BIOSCIENCE announced the unveiling of its quarterly earnings, and analysts have taken a cautious stance in the face of the news. The stock opened at $24.8 before closing the day at $24.3, representing a slight decrease of 2.6% from its prior closing price of 25.0. This marks a significant decrease from the opening price, and analysts are wary of any further potential negative impacts that the quarterly earnings could bring to the stock’s price. As such, investors should take a more cautious approach when considering TWIST BIOSCIENCE’s stock in the near future. Live Quote…
Analysis – Twist Bioscience Intrinsic Stock Value
At GoodWhale, we recently conducted an analysis of TWIST BIOSCIENCE‘s fundamentals. Our proprietary Valuation Line indicates that the intrinsic value of TWIST BIOSCIENCE share is around $104.1. However, at present the stock is trading at $24.3, representing a 76.7% discount to our estimate of its true worth. This suggests that TWIST BIOSCIENCE’s stock is currently significantly undervalued. More…
Peers
It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.
– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)
FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.
FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.
FoundHTG has a market cap of $6.07M and a ROE of -156.17%.
– Proteome Sciences PLC ($LSE:PRM)
Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.
– Genedrive PLC ($LSE:GDR)
Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.
Summary
Twist Bioscience is set to release its quarterly earnings report, and analysts have a moderately cautious outlook for the biotech firm. Although the company has made great strides in the field of synthetic biology and has achieved several notable accomplishments, investors are wary about its ability to generate consistent returns. Analysts suggest that investors should watch closely for changes in the company’s financials, how successful its research and development efforts are, and any new product announcements. The success of Twist Bioscience could be a bellwether for the industry overall and could provide investors with an opportunity to capitalize on any positive developments.
